The Trump administration has proposed a new rule aimed at limiting federal funding that does not "advance" presidential policies. This proposal was announced in late May [1]. If implemented, the rule would give political appointees significant oversight over grants intended to support scientific research, education initiatives, and infrastructure projects. Critics argue this could hinder progress on important medical advancements like treatments for diseases such as Alzheimer's, Parkinson's, and cancer [2].
The proposed changes have also raised concerns about their potential impact on vulnerable communities. Letters to the editor published in response to the proposal highlight fears that these measures could undermine efforts to advance scientific research and development [2]. Additionally, critics suggest that the rule could lead to slower progress in American research due to reduced funding and support from the government.
Furthermore, the administration's plan includes restrictions on researchers' ability to share their findings and collaborate internationally. This aspect of the proposal has been particularly contentious, as it could make scientific collaboration more challenging [3]. Critics argue that such limitations would not only hinder innovation but also make American research slower, costlier, and harder to share globally.